Free HRT Patient Monitoring & Safety Guidelines Questions and Answers — Questions and Answers
Question 1: Which lab value should be monitored to detect polycythemia in patients on testosterone therapy?
- TSH
- Hematocrit (Correct answer)
- FSH
- Calcium
Correct answer: Hematocrit
Polycythemia, a common side effect of testosterone therapy, is characterized by an increase in red blood cell mass. Hematocrit, which measures the percentage of red blood cells in the blood, is the primary lab value monitored to detect and assess the severity of polycythemia. Elevated hematocrit levels warrant dose adjustment or cessation of testosterone therapy to reduce cardiovascular risks.
Question 2: What is a common side effect of oral estrogen therapy that should be monitored?
- Constipation
- Thromboembolism (Correct answer)
- Blurred vision
- Dry mouth
Correct answer: Thromboembolism
Oral estrogen therapy is associated with an increased risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. This is because oral estrogen undergoes first-pass metabolism in the liver, which can affect the production of clotting factors. This risk is a significant safety concern that requires careful patient selection and monitoring.
Question 3: Which patient history detail would be a contraindication for estrogen replacement therapy?
- High cholesterol
- Family history of diabetes
- History of breast cancer (Correct answer)
- Mild anxiety
Correct answer: History of breast cancer
A history of breast cancer is a strong contraindication for estrogen replacement therapy. Estrogen can stimulate the growth of certain types of breast cancer cells, potentially leading to recurrence or progression of the disease. Therefore, HRT containing estrogen is generally avoided in individuals with a personal history of breast cancer.
Question 4: What is an important safety consideration when prescribing HRT for patients with cardiovascular disease?
- Recommend only high-dose patches
- Prescribe without screening
- Evaluate cardiovascular risk (Correct answer)
- Use oral estrogen exclusively
Correct answer: Evaluate cardiovascular risk
When prescribing HRT for patients with cardiovascular disease, it is crucial to thoroughly evaluate their individual cardiovascular risk. HRT, particularly oral estrogen, can influence cardiovascular events, and the risks and benefits must be carefully weighed. This involves assessing factors like age, existing conditions, and the type of HRT to ensure patient safety.
Question 5: Which symptom may indicate estrogen overdose in patients undergoing HRT?
- Increased hunger
- Nausea (Correct answer)
- Muscle cramps
- Dry eyes
Correct answer: Nausea
Nausea is a common symptom that can indicate estrogen overdose or excessively high estrogen levels in patients undergoing HRT. Other symptoms might include breast tenderness, bloating, or headaches. Monitoring for such symptoms helps clinicians adjust the estrogen dose to achieve optimal therapeutic levels without adverse effects.
Question 6: How often should bone mineral density be assessed in postmenopausal women on long-term HRT?
- Every 6 months
- Every 3–5 years
- Every 1–2 years (Correct answer)
- Only at the start of therapy
Correct answer: Every 1–2 years
Bone mineral density (BMD) should be assessed periodically in postmenopausal women on long-term HRT to monitor its effectiveness in preventing osteoporosis. While HRT can help maintain bone density, regular checks, typically every 1-2 years, are recommended. This frequency helps ensure the therapy is achieving its desired effect and guides treatment decisions.
Free HRT Patient Monitoring & Safety Guidelines Questions and Answers
Which lab value should be monitored to detect polycythemia in patients on testosterone therapy?